Parathyroid hormone pulsatility: Physiological and clinical aspects

Bone Research

Volumn 3, Issue , 2015, Pages

  Chiavistelli, Silvia ^a   Giustina, Andrea ^a   Mazziotti, Gherardo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934976194     PISSN: 20954700     EISSN: 20956231     Source Type: Journal    
DOI: 10.1038/boneres.2014.49     Document Type: Review

References (50)

1. Veldhuis JD, Keenan DM, Pincus SM. Motivations and methods for analyzing pulsatile hormone secretion. Endocr Rev 2008; 29: 823-864.
2. Samuels MH, Veldhuis JD, Henry P, Ridgway EC. Pathophysiology of pulsatile and copulsatile release of thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, and alpha-subunit. J Clin Endocrinol Metab 1990; 71: 425-432.
3. Wehrenberg WB, Giustina A. Basic counterpoint: mechanisms and pathways of gonadal steroid modulation of growth hormone secretion. Endocr Rev. 1992; 13: 299-308.
4. Brogan RS, Fife SK, Conley LK, Giustina A, Wehrenberg WB. Effects of food deprivation on the GH axis: immunocytochemical and molecular analysis. Neuroendocrinology 1997; 65: 129-135.
5. GiustinaA, Bresciani E, BussiARet al. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly. J Clin Endocrinol Metab 1995; 80: 1333-1340.
6. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717-797.
7. Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 2013; 9: 265-276.
8. Giustina A, Mazziotti G. Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect. Endocrine 2014; 47: 354-356.
9. Giustina A, Berardelli R, Gazzaruso C, Mazziotti G. Insulin and GH-IGFI axis: endocrine pacer or endocrine disruptor? Acta Diabetol 2014; doi: 10.1007/s00592-014-0635-6.
10. Schmitt CP, HömmeM, Schaefer F. Structural organization and biological relevance of oscillatory parathyroid hormone secretion. Pediatr Nephrol 2005; 20: 346-351.
11. Woitge HW, Knothe A, Witte K et al. Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. J Bone Miner Res 2000; 15: 2443-2450.
12. Markowitz ME, Arnaud S, Rosen JF, Thorpy M, Laximinarayan S. Temporal interrelationships between the circadian rhythms of serum parathyroid hormone and calcium concentrations. J Clin Endocrinol Metab 1988; 67: 1068-1073.
13. Samuels MH, Veldhuis J,CawleyCet al. Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J Clin Endocrinol Metab 1993; 77: 399-403.
14. Harms HM, Kaptaina U, Külpmann WR, Brabant G, Hesch RD. Pulse amplitude and frequencymodulation of parathyroid hormone in plasma. J Clin Endocrinol Metab 1989; 69: 843-851.
15. Kitamura N, Shigeno C, Shiomi K et al. Episodic fluctuation in serum intact parathyroid hormone concentration in men. J Clin Endocrinol Metab 1990; 70: 252-263.
16. Schmitt CP, Schaefer F, Bruch A et al. Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium. J Clin Endocrinol Metab. 1996; 81: 4236-4243.
17. Bonadonna S, Burattin A, Nuzzo M et al. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 2005; 152: 199-205.
18. Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca21-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-800.
19. Schmitt CP, Schaefer F, Huber D et al. 1,25(OH)2-vitamin D3 reduces spontaneous and hypocalcemia-stimulated pulsatile component of parathyroid hormone secretion. J Am Soc Nephrol 1998; 9: 54-62.
20. Gram J, Junker P,Nielsen HK, Bollerslev J. Effects of short-termtreatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone 1998; 23: 297-302.
21. Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992; 7: 65-72.
22. Slovik DM, Rosenthal DI, Doppelt SH et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986; 1: 377-381.
23. Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 2012; 27: 2419-2428.
24. Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 2008; 6: 24-38.
25. Shinagawa Y, Inoue T, Katsushima T et al. Discovery of a potent and short-acting oral calcilytic with a pulsatile secretion of parathyroid hormone. ACS Med Chem Lett 2010; 2: 238-242.
26. Cabal A, Mehta K, Ross DS et al. A semimechanistic model of the timecourse of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans. J BoneMinerRes 2013; 28: 1830-1836.
27. ProcopioM, Barale M, Bertaina S et al. Cardiovascular risk andmetabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine 2014; 47: 581-589.
28. Walker MD, Fleischer JB, Di Tullio MR et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2010; 95: 2172-2179.
29. Mazziotti G, Maffezzoni F, DogaM, Hofbauer LC, Adler RA, Giustina A. Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatmentwith bone active-drugs. Bone 2014; 67: 175-180.
30. SamuelsMH, Veldhuis JD, Kramer P et al. Episodic secretion of parathyroid hormone in postmenopausal women: assessment by deconvolution analysis and approximate entropy. J Bone Miner Res 1997; 12: 616-623.
31. Mazziotti G, Cimino V, de Menis E et al. Active acromegaly enhances spontaneous parathyroid hormone pulsatility. Metabolism 2006; 55: 736-740.
32. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primay hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005; 257: 6-17.
33. Vignali E, Viccica G, Diacinti D et al.Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94: 2306-2312.
34. Harms HM, Schlinke E, Neubauer O et al. Pulse amplitude and frequency modulation of parathyroid hormone in primary hyperparathyroidism. J Clin Endocrinol Metab 1994; 78: 53-57.
35. Mazziotti G, Bilezikian JP, Canalis E, Cocchi D, Giustina A. New understanding and treatments for osteoporosis. Endocrine 2012; 41: 58-69.
36. North American Menopause Society. The role of calcium in peri-and postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006; 13: 862-877 ; quiz 878-880.
37. Harms HM, Neubauer O, Kayser C et al. Pulse amplitude and frequency modulation of parathyroid hormone in early postmenopausal women before and on hormone replacement therapy. J Clin Endocrinol Metab 1994; 78: 48-52.
38. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006; 17: 144-149.
39. Angeli A, Guglielmi G, Dovio A et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006; 39: 253-259.
40. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-1328.
41. Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002; 87: 4033-4041.
42. GiustinaA,Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008; 29: 535-559.
43. Mazziotti G, Bianchi A, Bonadonna S et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res 2006; 21: 520-528.
44. Giustina A, Casanueva FF, Cavagnini F et al. Pituitary Society and the European Neuroendocrine Association. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003; 26: 1242-1247.
45. Mazziotti G, Biagioli E, Maffezzoni F et al. Bone turnover, bone mineral density and fracture risk in acromegaly: ameta-analysis. J Clin Endocrinol Metab 2014; doi: 10.1210/jc.2014-2937.
46. Bonadonna S, Mazziotti G, Nuzzo M et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005; 20: 1837-1844.
47. Mazziotti G, Bianchi A, Bonadonna S et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 2008; 93: 4649-4655.
48. MazziottiG, BianchiA, Porcelli T et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 2013; 98: 3402-3410.
49. Legovini P, de Menis E, Breda F et al. Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations. J Endocrinol Invest 1997; 20: 434-438.
50. Kamenický P, Mazziotti G, Lombès M, Giustina A, Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 2014; 35: 234-281.